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Abstract
Background: Staphylococcus aureus (S.aureus) is a major cause of both healthcare and community acquired
infections. In developing countries, manual phenotypic tests are the mainstay for the identification of staphylococci
with the tube and slide coagulase tests being relied upon as confirmatory tests for S. aureus. The subjectivity
associated with interpretation of these tests may result in misidentification of coagulase negative staphylococci as
S.aureus. Given that antibiotic resistance is more prevalent in CONS, this may result in over estimation of methicillin
resistant S.aureus (MRSA) prevalence.
Methods: A review of susceptibility data from all non-duplicate S.aureus isolates generated between March 2011 and
May 2013 by the Vitek-2 (bioMérieux) automated system was performed by the authors. The data was generated routinely
from processed clinical specimens submitted to the microbiology laboratories for culture and sensitivity at the Aga Khan
University Hospital and Gertrude’s children’s hospital both situated in Nairobi.
Results: Antimicrobial susceptibility data from a total of 731 non-duplicate S.aureus isolates was reviewed. Majority
(79.2%) of the isolates were from pus swabs. Only 24 isolates were both cefoxitin and oxacillin resistant while 3 were
resistant to oxacillin but susceptible to cefoxitin giving an overall MRSA prevalence of 3.7% (27/731). None of the isolates
were resistant to mupirocin, linezolid, tigecycline, teicoplanin or vancomycin.
Conclusion: The prevalence of MRSA in this study is much lower than what has been reported in most African
countries. The significant change in antibiotic susceptibility compared to what has previously been reported in our
hospital is most likely a consequence of the transition to an automated platform rather than a trend towards lower
resistance rates.
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Background
Staphylococcus aureus (S. aureus) is a major cause of
both healthcare and community acquired infections and
is perhaps the single most common cause of healthcare-
associated infection throughout the world [1-3]. S. aur-
eus has developed resistance to virtually all antibiotic
classes available for clinical use and this has been
observed in various continents [1,3-7]. In Africa, methi-
cillin resistant S.aureus (MRSA) prevalence is quite
variable with prevalence’s as low as 4% and as high as
82% being reported [8].
A study carried out in Kenya in 1997 reported an
MRSA prevalence of 39.8% amongst S.aureus isolates
from a variety of clinical specimens at the national refer-
ral hospital in Nairobi [6]. A study looking at MRSA
prevalence in 8 African countries found it to be between
20% and 30% in Nigeria, Cameroon and Kenya. The
prevalence was less than 10% in Tunisia and Algeria.
Only 137 isolates from Kenya were assessed in this study
[4]. A retrospective analysis of bloodstream isolates at
the Aga Khan University Hospital Nairobi (AKUHN) in
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Kenya reported a 21% prevalence of MRSA. This study
looked at data obtained from 364 non duplicate isolates
collected from January 2003 to April 2008 [9]. A 2013
publication looking at S.aureus isolates causing skin and
soft tissue infections in 5 government run healthcare
facilities in Nairobi reported MRSA prevalence amongst
S.aureus to be 84.1%. This was out of 82 isolates col-
lected between 2005 and 2007 [10]. In most of the men-
tioned studies, identification of S.aureus was performed
using manual methods.
In developing countries, phenotypic tests are the main-
stay for the identification of staphylococci with the tube
and slide coagulase tests being relied upon as con-
firmatory tests for S.aureus. This is largely because human
plasma is readily available in most hospital based labora-
tories. Kateete et al. reported specificities for human and
sheep plasma tube coagulase tests of 11% and 8% respect-
ively in identifying S.aureus when compared to a polymer-
ase chain reaction (PCR) assay detecting the nuc gene
which is specific for S.aureus [11]. Sperber et al. demon-
strated that tube coagulase is only reliable when a firm
clot which doesn’t move on tipping the tube is considered
a positive reaction [12]. The subjectivity in interpreting
the tube coagulase contributes considerably to its low spe-
cificity which may result in coagulase negative staphylo-
cocci (CONS) being misidentified as S.aureus. Given that
antimicrobial resistance especially to methicillin is more
common in CONS [13], this can lead to over estimation
of MRSA prevalence as well as erroneous reporting of in-
creased levels of resistance to other antibiotics.
Automated systems offer better species identification
than manual methods as this is based on a larger panel of
standardized biochemical tests. In addition, antimicrobial
susceptibility is objectively assessed by automated deter-
mination of minimum inhibitory concentrations (MICs)
[14,15]. The use of automated identification systems is
fairly recent in Kenya and this transition may result in a
significant change in reported antimicrobial susceptibility
patterns. The AKUHN started using an automated identi-
fication system for routine diagnosis in January 2011 while
Gertrude’s Children’s Hospital (GCH) has used one since
2009.
We set out to describe the antimicrobial susceptibil-
ity patterns of over 700 S.aureus isolates from routine
clinical specimens as determined byVitek-2 (version
4.01, bioMerieux, Marcy-l’Etoile, France). Vitek-2 is
an automated identification and susceptibility testing
system that enables rapid determination of MICs. Its im-
proved performance over earlier rapid systems is due
to the larger number of wells in each card, enhanced
optics, and new algorithms based on kinetic analyses of
growth data. It has an Advanced Expert System (AES)
which provides standardized interpretive reading of these
MICs.
To the best of our knowledge, this is the first study
in East Africa that has reported S.aureus antibiotic
susceptibility for over 700 isolates all identified using
automated systems. Given the large number of isolates
and presumably better species identification, this study
gives a more accurate picture of S.aureus antimicrobial
susceptibility in Nairobi over the past 2 years and provides
a baseline against which data generated from similar auto-
mated systems in East Africa can be compared against.
Methods
AKUHN is a 300 bed private university teaching hospital
that was awarded international accreditation by the Joint
Commission International in September 2013. The
hospitals main laboratory is ISO15189:2007 accredited
by the South African National Accreditation Service
(SANAS) since 2010. GCH is a dedicated pediatric
hospital in Nairobi with a bed capacity of 105. Both
hospitals offer primary and tertiary care services with
clientele largely comprising middle to high social
economic status individuals residing in Nairobi and
its environs. Both hospital laboratories receive samples
from a network of satellite clinics located in and around
Nairobi.
A review of all consecutive non-duplicate S.aureus sus-
ceptibility data generated between March 2011 and May
2013 by the Vitek-2 (bioMérieux) automated system was
performed by the authors. The data was generated rou-
tinely from processed clinical specimens submitted to the
microbiology laboratories for culture and sensitivity. The
Vitek-2 card AST P580 was used for susceptibility
testing and interpretation of the MICs was based on
Clinical Laboratory Standard Institute guidelines [16].
The antibiotics tested and reported included penicillin,
oxacillin, cefoxitin, gentamicin, amikacin, trimethoprim/
sulfamethoxazole (TMP/SMX), levofloxacin, moxifloxacin,
teicoplanin, vancomycin, linezolid, tetracycline, tigecyc-
line, rifampicin, mupirocin, clindamycin, erythromycin
and tobramycin. For oxacillin a cut off ≥4 ug/ml was con-
sidered resistant while for cefoxitin, a positive screen by
Vitek-2 was considered resistant. As per the CLSI guide-
lines, a S.aureus isolate found to be resistant to either
cefoxitin or oxacillin was reported as an MRSA.
The AKUHN and GCH ethics committees gave per-
mission for the use of antimicrobial susceptibility data
obtained from cultures done on patient samples.
Statistics
Antibiotic susceptibility was expressed as a percentage
of all S.aureus isolates. Comparison of antibiotic suscep-
tibility and sample types between AKUHN and GCH
isolates was done using chi-square or fishers exact tests
where appropriate. All analysis was two tailed. A p-value
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less than 0.05 was considered statistically significant.
Statistical analysis was performed using SPSS version 21.
Results
Antimicrobial susceptibility data from a total of 731 non-
duplicate S.aureus isolates was reviewed with AKUHN
and GCH contributing 529 and 202 respectively. Pus
swabs formed the bulk of the specimens comprising 79.2%
with majority coming from patients with skin and soft
tissue infections. The distribution of the clinical specimens
was as shown in Table 1.
Only 24 isolates were both cefoxitin and oxacillin resist-
ant while 3 were resistant to oxacillin but susceptible to
cefoxitin. Including these 3 isolates, the overall MRSA
prevalence was 3.7% (27/731). The 3 isolates were from
skin and soft tissue infections and were all susceptible to
teicoplanin, tigecycline, vancomycin, linezolid and rifampi-
cin. One of the isolates was only resistant to oxacillin and
penicillin while the other 2 isolates in addition to being
resistant to oxacillin and penicillin were also resistant to
erythromycin and tetracycline with intermediate suscepti-
bility to levofloxacin. One of the isolates was also resistant
to trimethoprim/sulfamethoxazole, tobramycin and moxi-
floxacin while the other had inducible clindamycin resist-
ance. The MRSA prevalence in blood stream isolates was
6.5% (3/46).
None of the S.aureus isolates was resistant to mupirocin,
vancomycin, teicoplanin, tigecycline or linezolid. Resist-
ance was highest to penicillin at 92.2% and trimethoprim-
sulfamethoxazole at 42.1% as shown in Table 2.
Comparison of susceptibility between AKUHN and
GCH isolates showed significantly less susceptibility in
AKUHN isolates to oxacillin, levofloxacin and tobramycin.
Generally, isolates from GCH were more susceptible to
the antibiotics tested as shown in Table 3.
All MRSA isolates were susceptible to tigecycline, mupir-
ocin, linezolid, teicoplanin and vancomycin as shown in
Figure 1.
Table 1 Table showing the proportion of different
specimen types from which Staphylococcus aureus
isolates were obtained at AKUHN and GCH
Specimen AKUHN GCH Total
n (%) n (%) n (%)
Pus swabs 395 (74.7%) 184 (91.1%) 579 (79.2%)
Blood 40 (7.6%) 6 (3.0%) 46 (6.3%)
Urine 8 (1.5%) 6 (3.0%) 14 (1.9%)
Screening swabs 48 (9.1%) 2 (1.0%) 50 (6.8%)
Lower respiratory tract 17 (3.2%) 1 (0.5%) 18 (2.5%)
Miscellaneousa 21 (4.0%) 3 (1.5%) 24 (3.3%)
Total 529 (100.0%) 202 (100.0%) 731 (100.0%)
aThese consisted of ascitic fluid, knee aspirates, vaginal swabs and isolates
where the source was not indicated.
Table 2 Table showing antibiotic susceptibility of
Staphylococcus aureus isolates
Antibiotic Susceptible Intermediate Resistant
No. (%) No. (%) No. (%)
Penicillin 57 (7.8%) 0 (0.0%) 674 (92.2%)
Oxacillin 704 (96.3%) 0 (0.0%) 27 (3.7%)
Cefoxitin 707 (96.7%) 0 (0.0%) 24 (3.3%)
Erythromycin 645 (88.2%) 1 (0.1%) 85 (11.7%)
Clindamycina 658 (90.0%) 0 (0.0%) 73 (10.0%)
Gentamicin 710 (97.1%) 7 (1.0%) 14 (1.9%)
Tobramycin 708 (96.8%) 5 (0.7%) 18 (2.5%)
Levofloxacin 687 (94.0%) 31 (4.2%) 13 (1.8%)
Moxifloxacin 724 (99.1%) 1 (0.1%) 6 (0.8%)
Linezolid 731 (100.0%) 0 (0.0%) 0 (0.0%)
Mupirocin 731 (100.0%) 0 (0.0%) 0 (0.0%)
Rifampicin 725 (99.2%) 3 (0.4%) 3 (0.4%)
TMP/SMXb 423 (57.9%) 0 (0.0%) 308 (42.1%)
Tetracycline 618 (84.5%) 0 (0.0%) 113 (15.5%)
Tigecycline 731 (100.0%) 0 (0.0%) 0 (0.0%)
Teicoplanin 731 (100.0%) 0 (0.0%) 0 (0.0%)
Vancomycin 731 (100.0%) 0 (0.0%) 0 (0.0%)
a59 isolates were susceptible to clindamycin based on MICs but were reported
as resistant as they had inducible clindamycin resistance.
bTMP/SMX-Trimethoprim/Sulfamethoxazole.
Table 3 Comparison of S.aureus antibiotic susceptibility
between AKUHN and GCH isolates
Antibiotic AKUHN (N = 529) GCH (N = 202) P-value
n (%) n (%)
Penicillin 46 (8.7%) 11 (5.4%) 0.166
Oxacillin 504 (95.3%) 200 (99.0%) 0.015
Erythromycin 459 (86.8%) 186 (92.1%) 0.054
Clindamycina 473 (89.4%) 185 (91.6%) 0.412
Gentamicin 510 (96.4%) 200 (99.0%) 0.080
Tobramycin 506 (95.7%) 202 (100.0%) 0.001
Levofloxacin 487 (92.1%) 200 (99.0%) 0.000
Moxifloxacin 522 (98.7%) 202 (100.0%) 0.199
Linezolid 529 (100.0%) 202 (100.0%) 1.000
Mupirocin 529 (100.0%) 202 (100.0%) 1.000
Rifampicin 524 (99.1%) 201 (99.5%) 1.000
TMP/SMXb 317 (59.9%) 106 (52.5%) 0.079
Tetracycline 446 (84.3%) 172 (85.1) 0.820
Tigecycline 529 (100.0%) 202 (100.0%) 1.000
Teicoplanin 529 (100.0%) 202 (100.0%) 1.000
Vancomycin 529 (100.0%) 202 (100.0%) 1.000
aAfter adjusting for inducible clindamycin resistance.
bTMP/SMX-Trimethoprim/Sulfamethoxazole.
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Discussion
Antimicrobial susceptibility surveillance is important as it
aids in identifying local resistance trends which impacts
on the management of both hospital and community-
acquired infections. We have previously reported an
MRSA prevalence of 21% in S.aureus bacteremia isolates
collected between January 2003 and April 2008 at
AKUHN [9]. This was a retrospective review of labora-
tory susceptibility data that relied on the use of manual
identification methods and susceptibility by disc diffusion.
The overall MRSA prevalence of 3.7% for all specimen
types and 6.5% in blood isolates in this study is therefore
much lower than what was anticipated. Whether this
reflects a true decline in methicillin resistance or is a
result of better diagnostic methods is a question that can
only be answered by continuous monitoring of trends in
S.aureus susceptibility. A study carried out in 2010 that
investigated nasal carriage of MRSA by healthcare workers
(HCWs) at AKUHN found that 45 out of 246 randomly
selected HCWs were carriers of S.aureus but none of the
isolates were MRSA even after performing genotypic tests
[17]. This low prevalence is in complete contrast to a
recently published study that reported MRSA prevalence
in S.aureus isolates from 5 public hospitals in Nairobi to
be 84.1% [10]. In this study, manual bench techniques
were used to identify S.aureus and to perform antimicro-
bial susceptibility. In as much as the patient population in
public and private hospitals differ in terms of the social
economic status, it is unlikely that this can explain the
marked difference in MRSA prevalence. We hypothesize
that the marked differences in MRSA prevalence amongst
various hospitals in Nairobi is a consequence of the different
laboratory techniques used to correctly identify MRSA.
A systematic review looking at MRSA in Africa found
no decreasing trend in MRSA prevalence in individual
countries except possibly for South Africa. This review
included only articles published after 2005 and that had
more than 100 isolates analyzed. Very few countries
reported an MRSA prevalence less than 10% [8]. The low
prevalence we report is however not unique in Africa. In
Madagascar, Randrianirina et al. reported prevalence’s
of 4.4% and 6.5% in hospital and community acquired
S.aureus isolates respectively. Most of the isolates
were community-acquired and largely originated from
genital, urinary and pus specimens collected between
January 2001 and December 2005 [18]. In Eritrea, a
prevalence of 9% was reported in S.aureus isolates from
pus and ear discharge [19]. In Gabon, the prevalence was
5.8% in isolates obtained from a variety of specimens
collected between 2009 and 2012 [20]. In most of these
studies, antimicrobial susceptibility testing was performed
using disc diffusion and not an automated system.
Out of 27 oxacillin resistant isolates in this study, 3 were
cefoxitin susceptible. A possible mechanism of resistance
in these isolates is hyper-production of beta lactamase
as is commonly found in Borderline oxacillin resistant
S.aureus (BORSA) isolates [21]. However, these isolates
all had oxacillin MICs >4 ug/ml. Typically, BORSA iso-
lates have an MIC between 1 and 4 ug/mL. The clinical
significance of this mechanism of resistance is not known
but such isolates are still reported as MRSA due to the
possibility of treatment failure if beta lactam antibiotics
are used [22]. Confirmation of the mechanism of resist-
ance in these isolates is required given the trend towards
adoption of PCR based diagnostic technologies targeted at
identifying only the mecA gene. In addition, some of the
Figure 1 Antibiotic susceptibility of MRSA isolates (N = 27). *After adjusting for inducible clindamycin ;resistance. **TMP/SMX-Trimethoprim/
Sulfamethoxazole.
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chromogenic plates used to identify MRSA are unable to
identify those that do not have the mecA gene [23].
Resistance to trimethoprim/Sulfamethoxazole (TMP/
SMX) was 42.1%. Various African studies have reported
resistance ranging from 0% to 100% [8]. However, the
marked heterogeneity in these studies makes it difficult to
comment on the reasons for the differences seen. In South
Africa, Kwa Zulu Natal province, 30.8% of S.aureus isolated
in 2001 and 2002 from various clinical specimens were re-
sistant to TMP/SMX. A study looking at blood isolates in 7
private pathology practices in South Africa reported resist-
ance of 29% [24]. In Gabon, non-susceptible isolates only
comprised 8.3% of all S.aureus isolates from non-invasive
specimens [20]. A study in Ghana looking at 308 S.aureus
isolates from diverse specimens found only 4% to be resist-
ant to TMP/SMX [25]. TMP/SMX is a cheap oral drug
with good bio-availability and broad spectrum cover
that has been thought to be an ideal alternative in
treating skin and soft tissue infections (SSIs) caused by
MSSA and community acquired MRSA (CA-MRSA)
[26,27]. The high resistance seen in this study rules it out
as an option for empiric treatment of SSIs at AKUHN and
GCH.
Resistance to erythromycin and clindamycin was 11.7%
and 10.0% respectively. Inducible clindamycin resistance
was seen in 8.1% of isolates that were susceptible based on
CLSI MIC cut offs [16]. Failure to test for inducible
clindamycin resistance would have resulted in clindamycin
resistance being reported as 1.9%. This highlights the
importance of modifying clindamycin susceptibility for
inducible phenotypes given that failure to do so can result
in patients being treated with clindamycin which could
result in treatment failure [28].
All isolates were susceptible to mupirocin, linezolid,
vancomycin, teicoplanin and tigecycline. Generally, S.
aureus resistance to most of these antibiotics is low in
Africa [8]. Rifampicin resistance was 11.1% in MRSA
isolates compared to 52.8% in MRSA isolates from
public diagnostic laboratories in South Africa [29].
Given South Africa’s high incidence of tuberculosis
and subsequent widespread use of rifampicin, it has
been hypothesized that selective pressure has resulted
in the emergence of rifampicin resistant MRSA.
Isolates from AKUHN were generally more resistant
to most antibiotics compared to GCH isolates. We can
only hypothesize that this may be a result of differences
in antibiotic pressure in the two hospitals or may be as a
result of the difference in population given that GCH
only caters for the pediatric age group while AKUHN
caters for mainly an adult population. The differences
seen could also be a chance finding resulting from the
multiple comparisons performed.
This study was limited by the fact that antibiotic resistance
data was not stratified according to whether the infections
were hospital or community acquired. Generally, commu-
nity acquired isolates are less resistant compared to
nosocomial isolates [30]. A second limitation is that
the data was obtained only from 2 private hospitals in
Nairobi hence limiting the generalizability of the results to
other hospitals in Nairobi. Despite this limitation, AKUHN
and GCH are both primary and tertiary healthcare facilities
with a large network of satellite clinics and laboratories in
and around Nairobi. Therefore, the susceptibility data
presented from over 700 unique isolates can serve as a
point of reference for the antimicrobial susceptibility
of S.aureus isolates in Nairobi.
Conclusions
The prevalence of MRSA in this study is much lower
than what has been reported in most African countries.
The significant change in antibiotic susceptibility compared
to what has previously been reported is most likely a
consequence of the transition to an automated platform
rather than a trend towards lower resistance rates. It
is likely that as more hospitals in Africa adopt similar
systems, changes in previously reported susceptibility
patterns will be observed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GO conceived and participated in the design of the study, performed
the statistical analysis and helped to draft the manuscript. BK and GR
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript. None of
the authors had funding for this work.
Author details
1Aga Khan University Hospital Nairobi, P.O. Box 30270–00100, Nairobi, Kenya.
2Gertrudes Children’s Hospital, P.O Box 42325 – 00100, Nairobi, Kenya.
Received: 11 January 2014 Accepted: 27 November 2014
References
1. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ: Epidemiology and
susceptibility of 3,051 Staphylococcus aureus isolates from 25 university
hospitals participating in the European SENTRY study. J Clin Microbiol
2001, 39:3727–3732.
2. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998,
339:520–532.
3. McDonald LC: Trends in antimicrobial resistance in health care-associated
pathogens and effect on treatment. Clin Infect Dis 2006, 42(Suppl 2):S65–S71.
4. Kesah C, Ben Redjeb S, Odugbemi TO, Boye CS, Dosso M, Ndinya Achola JO,
Koulla-Shiro S, Benbachir M, Rahal K, Borg M: Prevalence of methicillin-
resistant Staphylococcus aureus in eight African hospitals and Malta.
Clin Microbiol Infect 2003, 9:153–156.
5. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M,
Lapetina E, Gemmen E: The burden of Staphylococcus aureus infections on
hospitals in the United States: an analysis of the 2000 and 2001
Nationwide Inpatient Sample Database. Arch Intern Med 2005,
165:1756–1761.
6. Omari MA, Malonza IM, Bwayo JJ, Mutere AN, Murage EM, Mwatha AK,
Ndinya-Achola JO: Pattern of bacterial infections and antimicrobial
susceptibility at the Kenyatta National Hospital, Nairobi, Kenya.
East Afr Med J 1997, 74:134–137.
Omuse et al. BMC Infectious Diseases 2014, 14:669 Page 5 of 6
http://www.biomedcentral.com/1471-2334/14/669
7. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P,
Bruinsma N, Monen J, Witte W, Grundman H: Methicillin-resistant
Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 2004,
10:1627–1634.
8. Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP: MRSA in Africa:
filling the global map of antimicrobial resistance. PLoS One 2013,
8:e68024.
9. Kohli R, Omuse G, Revathi G: Antibacterial susceptibility patterns of blood
stream isolates in patients investigated at the Aga Khan University
Hospital Nairobi. East Afr Med J 2010, 87:74–80.
10. Maina EK, Kiiyukia C, Wamae CN, Waiyaki PG, Kariuki S: Characterization of
methicillin-resistant Staphylococcus aureus from skin and soft tissue
infections in patients in Nairobi, Kenya. Int J Infect Dis 2012, 17:e115–e119.
11. Kateete DP, Kimani CN, Katabazi FA, Okeng A, Okee MS, Nanteza A, Joloba ML,
Najjuka FC: Identification of Staphylococcus aureus: DNase and Mannitol salt
agar improve the efficiency of the tube coagulase test.
Ann Clin Microbiol Antimicrob 2010, 9:23.
12. Sperber WH, Tatini SR: Interpretation of the tube coagulase test for
identification of Staphylococcus aureus. Appl Microbiol 1975, 29:502–505.
13. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M:
Survey of infections due to Staphylococcus species: frequency of
occurrence and antimicrobial susceptibility of isolates collected in the
United States, Canada, Latin America, Europe, and the Western Pacific
region for the SENTRY Antimicrobial Surveillanc. Clin Infect Dis 2001,
32(Suppl 2):S114–S132.
14. Winstanley T, Courvalin P: Expert systems in clinical microbiology.
Clin Microbiol Rev 2011, 24:515–556.
15. Spanu T, Sanguinetti M, Ciccaglione D, D’Inzeo T, Romano L, Leone F, Fadda G:
Use of the VITEK 2 system for rapid identification of clinical isolates of
Staphylococci from bloodstream infections. J Clin Microbiol 2003,
41:4259–4263.
16. CLSI: Performance standards for antimicrobial susceptibility testing; Twentieth
informational supplement. M100-S20, Vol. 29 No 3. Wayne, PA: Clinical
Laboratory Standards Institute; 2010.
17. Omuse G, Kariuki S, Revathi G: Unexpected absence of meticillin-resistant
Staphylococcus aureus nasal carriage by healthcare workers in a tertiary
hospital in Kenya. J Hosp Infect 2012, 80:71–73.
18. Randrianirina F, Soares J-L, Ratsima E, Carod J-F, Combe P, Grosjean P,
Richard V, Talarmin A: In vitro activities of 18 antimicrobial agents against
Staphylococcus aureus isolates from the Institut Pasteur of Madagascar.
Ann Clin Microbiol Antimicrob 2007, 6:5.
19. Naik D, Teclu A: A study on antimicrobial susceptibility pattern in clinical
isolates of Staphylococcus aureus in Eritrea. Pan Afr Med J 2009, 3:1.
20. Alabi AS, Frielinghaus L, Kaba H, Kösters K, Huson MA, Kahl BC, Peters G,
Grobusch MP, Issifou S, Kremsner PG, Schaumburg F: Retrospective analysis
of antimicrobial resistance and bacterial spectrum of infection in Gabon,
Central Africa. BMC Infect Dis 2013, 13:455.
21. Chambers HF: Methicillin resistance in staphylococci: molecular and
biochemical basis and clinical implications. Clin Microbiol Rev 1997,
10:781–791.
22. Skinner S, Murray M, Walus T, Karlowsky JA: Failure of cloxacillin in
treatment of a patient with borderline oxacillin-resistant Staphylococcus
aureus endocarditis. J Clin Microbiol 2009, 47:859–861.
23. Buchan BW, Ledeboer NA: Identification of two borderline oxacillin-
resistant strains of Staphylococcus aureus from routine nares swab
specimens by one of three chromogenic agars evaluated for the
detection of MRSA. Am J Clin Pathol 2010, 134:921–927.
24. Brink A, Moolman J, da Silva MC, Botha M: Antimicrobial susceptibility
profile of selected bacteraemic pathogens from private institutions in
South Africa. S Afr Med J 2007, 97:273–279.
25. Egyir B, Guardabassi L, Sørum M, Nielsen SS, Kolekang A, Frimpong E,
Addo KK, Newman MJ, Larsen AR: Molecular Epidemiology and
Antimicrobial Susceptibility of Clinical Staphylococcus aureus from
Healthcare Institutions in Ghana. PLoS One 2014, 9:e89716.
26. Roberts S, Chambers S: Diagnosis and management of Staphylococcus
aureus infections of the skin and soft tissue. Intern Med J 2005,
35(Suppl 2):S97–S105.
27. Sabol KE, Echevarria KL, Lewis JS: Community-associated methicillin-
resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother
2006, 40:1125–1133.
28. Drinkovic D: Clindamycin treatment of Staphylococcus aureus expressing
inducible clindamycin resistance. J Antimicrob Chemother 2001,
48:315–316.
29. Marais E, Aithma N, Perovic O, Oosthuysen WF, Musenge E, Dusé AG:
Antimicrobial susceptibility of methicillin-resistant Staphylococcus
aureus isolates from South Africa. S Afr Med J 2009, 99:170–173.
30. Salmenlinna S, Lyytikäinen O, Vuopio-Varkila J: Community-acquired
methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis
2002, 8:602–607.
doi:10.1186/s12879-014-0669-y
Cite this article as: Omuse et al.: Low prevalence of methicillin resistant
Staphylococcus aureus as determined by an automated identification
system in two private hospitals in Nairobi, Kenya: a cross sectional
study. BMC Infectious Diseases 2014 14:669.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Omuse et al. BMC Infectious Diseases 2014, 14:669 Page 6 of 6
http://www.biomedcentral.com/1471-2334/14/669
